{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:39:57Z","timestamp":1778884797612,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"am","delay-in-days":400,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN2272201000033I\/HHSN27200002 A65"],"award-info":[{"award-number":["HHSN2272201000033I\/HHSN27200002 A65"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NHLBI 1R01HL137282"],"award-info":[{"award-number":["NHLBI 1R01HL137282"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007899","name":"University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015006","name":"Western Alliance Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["HRD-1101728"],"award-info":[{"award-number":["HRD-1101728"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["0619599"],"award-info":[{"award-number":["0619599"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["15\\u20131648"],"award-info":[{"award-number":["15\\u20131648"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000888","name":"W. M. Keck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pupt.2020.101975","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T02:25:10Z","timestamp":1604111110000},"page":"101975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles\/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery"],"prefix":"10.1016","volume":"64","author":[{"given":"Alexan I.","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria F.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason X.-J","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Don","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3993-9210","authenticated-orcid":false,"given":"Heidi M.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pupt.2020.101975_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pupt.2020.101975_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.pupt.2020.101975_bib3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ppul.21300","article-title":"Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis","volume":"45","author":"Hayes","year":"2010","journal-title":"Pediatr. Pulmonol."},{"issue":"5","key":"10.1016\/j.pupt.2020.101975_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-011-9311-6","article-title":"Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure","volume":"189","author":"Hayes","year":"2011","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.pupt.2020.101975_bib5","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1378\/chest.121.6.1988","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"121","author":"Soubani","year":"2002","journal-title":"CHEST Journal"},{"issue":"4","key":"10.1016\/j.pupt.2020.101975_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn","year":"2009","journal-title":"Rev. Iberoam. De. Micol."},{"key":"10.1016\/j.pupt.2020.101975_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S4937","article-title":"Nanomedicine in pulmonary delivery","volume":"4","author":"Mansour","year":"2009","journal-title":"Int. J. Nanomed."},{"issue":"12","key":"10.1016\/j.pupt.2020.101975_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"issue":"2","key":"10.1016\/j.pupt.2020.101975_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolized delivery of antifungal agents","volume":"4","author":"Le","year":"2010","journal-title":"Current fungal infection reports"},{"key":"10.1016\/j.pupt.2020.101975_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14356\/kona.2010005","article-title":"Surface analytical techniques in solid-state particle characterization: implications for predicting performance in dry powder inhalers. Invited paper","volume":"28","author":"Wu","year":"2010","journal-title":"KONA Powder & Particle Journal"},{"issue":"1\u20132","key":"10.1016\/j.pupt.2020.101975_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0169-409X(90)90012-H","article-title":"Liposomes as drug delivery systems to the lung","volume":"5","author":"Kellaway","year":"1990","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.pupt.2020.101975_bib12","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.addr.2006.07.012","article-title":"in vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery","volume":"58","author":"Sakagami","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.pupt.2020.101975_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0168-3659(93)90180-D","article-title":"Pulmonary delivery of liposomes","volume":"24","author":"Schreier","year":"1993","journal-title":"J. Contr. Release"},{"issue":"2","key":"10.1016\/j.pupt.2020.101975_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbamem.2004.05.003","article-title":"New lipid formulation of amphotericin B: spectral and microscopic analysis","volume":"1664","author":"Larabi","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.pupt.2020.101975_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejps.2013.10.016","article-title":"Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate\/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery","volume":"52","author":"Li","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"6","key":"10.1016\/j.pupt.2020.101975_bib16","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1208\/s12249-014-0182-z","article-title":"High-performing dry powder inhalers of paclitaxel DPPC\/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies","volume":"15","author":"Meenach","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.pupt.2020.101975_bib17","first-page":"275","volume":"8","author":"Meenach","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.pupt.2020.101975_bib18","first-page":"3489","article-title":"Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate\/nanoparticulate powders for pulmonary inhalation aerosol delivery","volume":"8","author":"Duan","year":"2013","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.pupt.2020.101975_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00408-011-9360-x","article-title":"Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery","volume":"190","author":"Willis","year":"2012","journal-title":"Lung"},{"issue":"1\u20132","key":"10.1016\/j.pupt.2020.101975_bib20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2013.06.047","article-title":"Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols","volume":"455","author":"Park","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.pupt.2020.101975_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/pharmaceutics6020333","article-title":"Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers","volume":"6","author":"Muralidharan","year":"2014","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pupt.2020.101975_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ejps.2013.05.012","article-title":"Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer","volume":"49","author":"Meenach","year":"2013","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.pupt.2020.101975_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1039\/C5ME00004A","article-title":"Microparticulate\/Nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung nrf2\/keap-1 pathway","volume":"1","author":"Muralidharan","year":"2016","journal-title":"Molecular systems design & engineering"},{"issue":"17","key":"10.1016\/j.pupt.2020.101975_bib24","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.2174\/1381612822666160202142104","article-title":"In vitro pulmonary cell culture in pharmaceutical inhalation aerosol delivery: 2-D, 3-D, and in situ bioimpactor models","volume":"22","author":"F Acosta","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.pupt.2020.101975_bib25","first-page":"2617","volume":"29\/24","year":"2006"},{"issue":"3","key":"10.1016\/j.pupt.2020.101975_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2014.05.003","article-title":"Across the pulmonary epithelial barrier: integration of physicochemical properties and human cell models to study pulmonary drug formulations","volume":"144","author":"Haghi","year":"2014","journal-title":"Pharmacology & therapeutics"},{"issue":"3","key":"10.1016\/j.pupt.2020.101975_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jps.2600670334","article-title":"Ambiguities in IR and X\u2010ray characterization of amphotericin B","volume":"67","author":"Schwartzman","year":"1978","journal-title":"J. Pharmaceut. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2020.101975_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1166\/jnd.2014.1064","article-title":"Enhanced pulmonary administration of amphotericin B loaded in PEG-g-PLA nanoparticles: in vitro proof-of-concept and susceptibility against Candida spp. and Aspergillus spp","volume":"2","author":"Aoun","year":"2014","journal-title":"Journal of Nanopharmaceutics and Drug Delivery"},{"issue":"1","key":"10.1016\/j.pupt.2020.101975_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijpharm.2012.07.028","article-title":"Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization","volume":"436","author":"Nasr","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.pupt.2020.101975_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(94)90070-1","article-title":"Drug delivery to the respiratory tract using dry powder inhalers","volume":"101","author":"Timsina","year":"1994","journal-title":"Int. J. Pharm."},{"issue":"40","key":"10.1016\/j.pupt.2020.101975_bib31","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.2174\/1381612821666151008150457","article-title":"Amorphous or crystalline? A comparison of particle engineering methods and selection","volume":"21","author":"G Thakkar","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"issue":"10","key":"10.1016\/j.pupt.2020.101975_bib32","first-page":"1100","article-title":"Improvement of physico-mechanical properties of partially amorphous acetaminophen developed from hydroalcoholic solution using spray drying technique","volume":"16","author":"Sadeghi","year":"2013","journal-title":"Iranian journal of basic medical sciences"},{"issue":"1","key":"10.1016\/j.pupt.2020.101975_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00044011-200020010-00004","article-title":"In vitro comparison of three salbutamol-containing multidose dry powder inhalers","volume":"20","author":"Palander","year":"2000","journal-title":"Clin. Drug Invest."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:08:21Z","timestamp":1777608501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553920301802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":33,"alternative-id":["S1094553920301802"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101975","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles\/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101975"}}